Journal article
Titanocendichloride activity in cisplatin and doxorubicin-resistant human ovarian carcinoma cell lines
European journal of cancer (1990), Vol.29A(7), pp.1000-1002
01/01/1993
DOI: 10.1016/S0959-8049(05)80210-2
PMID: 8499130
Abstract
The activity of a new organometallic compound, titanocendichloride, was evaluated in doxorubicin- and cisplatin-resistant human ovarian carcinoma cell lines in vitro. Titanocendichloride showed no cross resistance to doxorubicin in two multidrug resistant sublines of A2780. Furthermore, the cell line A2780 CP3, which is about 20-fold resistant to cisplatin was only 2.5-fold resistant to titanocendichloride, indicating a lack of cross resistance between the two metal compounds. These results were confirmed in vivo where titanocendichloride showed a much stronger inhibitory effect in cisplatin-resistant human ovarian carcinoma xenografts than cisplatin.
Details
- Title: Subtitle
- Titanocendichloride activity in cisplatin and doxorubicin-resistant human ovarian carcinoma cell lines
- Creators
- A Harstrick - Leibniz University HannoverH J Schmoll - Leibniz University HannoverG Sass - MedacH Poliwoda - Leibniz University HannoverY Rustum - Roswell Park Cancer Institute
- Resource Type
- Journal article
- Publication Details
- European journal of cancer (1990), Vol.29A(7), pp.1000-1002
- DOI
- 10.1016/S0959-8049(05)80210-2
- PMID
- 8499130
- ISSN
- 0959-8049
- eISSN
- 1879-0852
- Language
- English
- Date published
- 01/01/1993
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984359833102771
Metrics
11 Record Views